Compare Amphastar Pharmaceuticals Inc (AMPH) vs McDonald's Corp (MCD) Price & Performance

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

McDonald's (MCD) trades at $274.48, down 0.64% for the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $3.41. Revenue grew to $26.89 billion in 2025, supported by a net income margin of 31.72%. Recent news highlights the launch of the 'McDonald's NEXT' strategy focusing on automation and customer experience improvements.

The outlook remains positive with a consensus price target of $322.45, implying significant upside. Strong fundamentals and analyst buy ratings (59.68%) support growth, though risks include inflationary pressures on franchisee margins and high long-term debt of $38.42 billion. The stock offers a solid dividend yield with recent payouts of $1.86 per share.